- Palmatine chloride
-
- $39.00 / 500mg
-
2025-07-10
- CAS:10605-02-4
- Min. Order:
- Purity: 99.47%
- Supply Ability: 10g
- Palmatine chloride
-
- $0.00 / 1kg
-
2025-06-13
- CAS:10605-02-4
- Min. Order: 1kg
- Purity: 90% 98% 99%
- Supply Ability: 1000 kg
- Palmatine hcl
-
- $0.00 / 25kg
-
2023-08-05
- CAS:10605-02-4
- Min. Order: 1kg
- Purity: CP2020
- Supply Ability: 10tons
|
| | Palmatine chloride Basic information |
| | Palmatine chloride Chemical Properties |
| Melting point | 205℃ | | storage temp. | Hygroscopic, Refrigerator, under inert atmosphere | | solubility | Chloroform (Slightly), DMSO (Slightly) | | form | Solid | | color | Yellow | | InChI | InChI=1S/C21H22NO4.ClH/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4;/h5-6,9-12H,7-8H2,1-4H3;1H/q+1;/p-1 | | InChIKey | RLQYRXCUPVKSAW-UHFFFAOYSA-M | | SMILES | C12=CC3=C(C(OC)=C(OC)C=C3)C=[N+]1CCC1C=C(OC)C(OC)=CC2=1.[Cl-] |
| | Palmatine chloride Usage And Synthesis |
| Description | Corydalis paUida yields this alkaloid which occurs in the quaternary base fraction.
The alkaloid is separated by droplet countercurrent chromatography and crystallizes from H20 as yellow-green needles. | | Description | Palmatine is an alkaloid that has been found in C. rhizoma and has diverse biological activities. It inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE; IC50s = 0.51 and 6.84 μM, respectively). Palmatine (20, 40, and 80 μM) reduces Zika virus infection of Vero cells in a concentration-dependent manner. In vivo, palmatine (50 and 100 mg/kg) reduces colonic myeloperoxidase (MPO) activity and IL-10, IL-1β, IL-6, and TNF-α levels, as well as protects mucosal integrity in a mouse model of colitis induced by dextran sulfate (DSS; ). It reduces stomach ulcer area in a rat model of acetic acid-induced gastric ulcers. Palmatine (10 and 20 mg/kg) reduces the number of small intestine and colon tumors in the ApcMin+/- mouse model of multiple intestinal neoplasia. | | Uses | Palmatine Chloride is a protoberberine alkaloid, as a potential anti-inflammatory and anti-hypertensive agent. | | Uses | antibacterial, antimalarial, uterine contractant | | in vivo | Palmatine (50 or 100 mg/kg; p.o.; daily for 7 days) ameliorates DSS (dextran sulfate sodium)-induced colitis and prevents infiltration of inflammatory cells[1].?
Palmatine (0-200 mg/kg; i.p.; once) attenuates D-galactosamine/Lipopolysaccharides (HY-D1056)-induced fulminant hepatic failure in mice[2].?
Palmatine (0-1 mg/kg; i.p.; 10 days) shows memory-enhancing activity in mice[4].?
Palmatine (33.75-135 mg/kg; p.o.; daily for 26 days) can effectively inhibit the growth of HCT-116 xenografts in mice[5]. | Animal Model: | DSS- induced Colitis BALB/c mice model (8-week-old)[1] | | Dosage: | 50 or 100 mg/kg | | Administration: | Orally, daily, for 7 days | | Result: | Ameliorated DSS-induced colitis and prevented infiltration of inflammatory cells; remarkably extended the colon length; significantly suppressed the colonic MPO activity. Decreased the levels of colonic inflammatory cytokines (TNF-α, IFN-γ, IL-1β, IL-6, IL-4 and IL-10); Protected mucosal integrity by modulating TJs protein and apoptosis proteins; Restored DSS-induced decreases of TJ protein ZO-1, ZO-2 and claudin-1; Reduced Bax expression and enhanced Bcl-2 expression at the dose of 100?mg/kg, prevented epithelial apoptosis and improved intestinal integrity. Prevented DSS-induced changes of gut microbiota in colitis mice. |
| Animal Model: | Male ICR mice (20–22 g), D-galactosamine/lipopolysaccharide (GalN/LPS)-induced fulminant hepatic failure model[2] | | Dosage: | 25, 50, 100, or 200 mg/kg | | Administration: | Intraperitoneal injection, 1 h before the GalN/LPS treatment | | Result: | Attenuated the mortality and serum aminotransferase activities increased by GalN/LPS. Prevented the increase of serum TNF-α and augmented that of serum IL-10. Decreased the TNF-a mRNA expression and increased the IL-10 mRNA expression. Attenuated the apoptosis of hepatocytes.
|
| Animal Model: | Swiss young male albino mice, with Scopolamine (HY-N0296)- and diazepam-induced amnesia model[4] | | Dosage: | 0.1, 0.5, 1 mg/kg | | Administration: | Intraperitoneal injection, 10 days | | Result: | Significantly improved learning and memory of mice at 0.5 and 1 mg/kg and did not show any significant effect on locomotor activity of the mice. Significantly reversed scopolamine- and diazepam-induced amnesia in mice. Significantly reduced brain acetylcholinesterase activity of mice. |
| Animal Model: | BALB/c-nude mice, HCT-116 xenograft model[5] | | Dosage: | 33.75, 67.5 and 135 mg/kg | | Administration: | Oral administration, once a day for 26 days | | Result: | The tumor volume and weight of the treatment group were significantly reduced. |
| | target | Antifection | | IC 50 | IDO-1: 3 μM (IC50, HEK 293-hIDO-1); IDO-1: 157 μM (IC50, rhIDO-1); WNV NS2B-NS3: 96 μM (IC50) | | References | Tani, Nakagura, Hattori, Yakugaku Zasshi, 95, 1103 (1975) |
| | Palmatine chloride Preparation Products And Raw materials |
|